CD276 and colorectal carcinoma: Targeting B7H3 may be a promising therapeutic option for patients with tumors that are resistant to PD-1/PD-L1 blockade, particularly in colorectal cancer (CRC) that expresses PD-L1 only in microsatellite instable tumors, which make up less than 15% of all cases [71].